BaladoCritique : club de lecture médical
LightNews LightNews
banner
baladocritique.bsky.social
BaladoCritique : club de lecture médical
@baladocritique.bsky.social
96 followers 100 following 450 posts
Baladodiffusion qui analyse les études de médecine interne/médecine familiale depuis 2016.
Éditeurs : Dr L. Lanthier, Dr M. Cauchon, Dr A. Mutchmore.
En collaboration avec l'Université de Sherbrooke (Québec).
https://www.usherbrooke.ca/baladocritique
Posts Replies Media Videos
Reposted by BaladoCritique : club de lecture médical
jaccjournals.bsky.social
#Obesity changes everything about #PulmonaryEmbolism from diagnosis to drug dosing 💊. This review exposes how body size complicates imaging, therapy, and survival. Guidelines must catch up.

🆕 in #JACC: https://bit.ly/4ibq8ox

#CardioSky
November 10, 2025 at 5:15 PM
Reposted by BaladoCritique : club de lecture médical
jama.com
RCT: Patients with #AFib who continued their usual caffeinated coffee intake after cardioversion experienced less recurrence of AF or atrial flutter compared to those who abstained from coffee and caffeine.

#AHA25 @ahascience.bsky.social

ja.ma/47FZkaR
Infographic titled JAMA, it discusses the effect of caffeinated coffee on recurrent atrial fibrillation (AF). The study with 200 patients, found less AF recurrence with coffee vs abstinence. Coffee: 47% recurrence. Abstinence: 64%.
November 9, 2025 at 3:00 PM
Reposted by BaladoCritique : club de lecture médical
nejm.org
In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: nej.md/43U5Ppo

#AHA25
Kaplan–Meier curves of the cumulative incidence of death from any cause, myocardial infarction, or heart failure (the composite primary end point).
November 9, 2025 at 4:14 PM
baladocritique.bsky.social
"Antidiabetic agents and dementia risk in type 2 diabetes: A systematic review and network meta‐analysis."
Publié en octobre dans Diabetes Obes Metab.
#MedSky #EndoSky #NeuroSky
dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/...
Error - Cookies Turned Off
dom-pubs.pericles-prod.literatumonline.com
November 9, 2025 at 2:05 PM
Reposted by BaladoCritique : club de lecture médical
jama.com
Liberal transfusion after major surgery did not reduce death or major cardiac event rates compared to restrictive thresholds in high-risk patients.

#AHA25 @ahascience.bsky.social

ja.ma/43koXNj
JAMA study: Liberal vs. restrictive transfusion strategies post-op. 1393 men, 31 women, avg age 69.9. 1428 patients randomized. Liberal transfusion: 9.1% event rate. Restrictive: 10.1%. Little difference in mortality observed.
November 8, 2025 at 10:15 PM
Reposted by BaladoCritique : club de lecture médical
nejm.org
In an interim analysis, sibeprenlimab, a humanized IgG2 monoclonal antibody that inhibits the proliferation-inducing ligand APRIL (a key driver of IgA nephropathy), reduced proteinuria as compared with placebo. nej.md/493Xtza

@asnkidney.bsky.social | #KidneyWk
A line plot of the least-squares geometric mean change in spot UPCR from baseline
November 8, 2025 at 4:35 PM
Reposted by BaladoCritique : club de lecture médical
nejm.org
ADAPT AF-DES trial: In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. nej.md/4nH8DgK

#AHA25
American Heart Association Scientific Sessions 2025 Original Article | Nov 8, 2025 | NEJM.org Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents Figure 2A. Net Adverse Clinical Events The NEJM identity sits at the bottom.
November 8, 2025 at 7:35 PM
Reposted by BaladoCritique : club de lecture médical
nejm.org
Among patients with atherosclerosis or diabetes but no previous myocardial infarction or stroke, evolocumab led to a lower risk of major adverse cardiovascular events than placebo. Full VESALIUS-CV trial results: nej.md/4oWrIN6

#AHA25
American Heart Association Scientific Sessions 2025 Original Article | Nov 8, 2025 | NEJM.org Evolocumab in Patients without a Previous Myocardial Infarction or Stroke Figure 1A. 3-Point MACE.   The NEJM identity sits at the bottom.
November 8, 2025 at 3:36 PM
baladocritique.bsky.social
"Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8)."
Publié ce jour dans @bmj.com
#MedSky #CardioSky
www.bmj.com/content/391/...
Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8)
Objective To assess the effect of intracoronary infusion of mesenchymal stem cells on the development of post-myocardial infarction heart failure. Design Phase 3 randomised clinical trial. Setting T...
www.bmj.com
November 8, 2025 at 3:40 PM
baladocritique.bsky.social
"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial."
Publié ce jour dans @thelancet.com.
#MedSky #EndoSky
www.thelancet.com/journals/lan...
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial
The cardioprotective effects of semaglutide were independent of baseline adiposity and weight loss and had only a small association with waist circumference, suggesting some mechanisms for benefit bey...
www.thelancet.com
November 8, 2025 at 3:38 PM
baladocritique.bsky.social
“Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial.”
Publié ce jour dans @thelancet.com.
#MedSky #CardioSky
www.thelancet.com/journals/lan...
Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial
In east Asian patients with HBR, 1-month DAPT did not reach non-inferiority to 3-month DAPT for net adverse clinical events. In patients without HBR, 3-month DAPT was non-inferior to 12-month DAPT reg...
www.thelancet.com
November 8, 2025 at 1:01 PM
baladocritique.bsky.social
“Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.”
Publié dans le @nejm.org.
#MedSky #NephSky
www.nejm.org/doi/full/10....
Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis | NEJM
Cardiovascular disease is the leading cause of death in patients receiving hemodialysis, yet effective preventive therapies remain limited. Supplementation with n−3 polyunsaturated fatty acids, esp...
www.nejm.org
November 8, 2025 at 12:30 PM
baladocritique.bsky.social
“Varicella-zoster virus reactivation and the risk of dementia.”
Publié en octobre dans Nature Medicine.
#MedSky #NeuroSky #IDSky
www.nature.com/articles/s41...
Varicella-zoster virus reactivation and the risk of dementia - Nature Medicine
Large-scale longitudinal health records reveal consistent association of varicella-zoster virus reactivation with dementia.
www.nature.com
November 7, 2025 at 2:06 AM
baladocritique.bsky.social
"Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents."
Publié ce jour dans le @nejm.org.
#MedSky
www.nejm.org/doi/full/10....
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents | NEJM
Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psoriasis. We conducted a phase 3, double-blind, randomiz...
www.nejm.org
November 6, 2025 at 12:34 PM
baladocritique.bsky.social
“Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.”
Publié ce jour dans le @nejm.org.
#MedSky #EndoSky
www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | NEJM
Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, doubl...
www.nejm.org
November 6, 2025 at 12:29 PM
Reposted by BaladoCritique : club de lecture médical
thelancet.com
"We must reflect on current prevention strategies in the context of the changing contribution of different cardiovascular conditions."

@nath-conrad.bsky.social & colleagues explore the evolving spectrum of cardiovascular disease: tinyurl.com/5c9pe8mj
The proportion of newly diagnosed cardiovascular disease in the UK, by individual condition, from 2000 to 2002 and 2017 to 2019. Proportions were calculated by dividing the age–sex-standardised incidence rate for the condition of interest by the sum of the age–sex-standardised incidence rates across all ten conditions. Copyright: 2025 Elsevier Ltd. All rights are reserved.
November 5, 2025 at 11:26 AM
Reposted by BaladoCritique : club de lecture médical
anticoagforum.bsky.social
📘 The October Rapid Recap is here — your monthly snapshot of the latest anticoagulation evidence, distilled for busy clinicians.

Each summary helps clinicians stay informed and apply emerging evidence directly to patient care.

👉 Read the full recap: acforum.org/web/scripts/...
November 4, 2025 at 4:30 PM
baladocritique.bsky.social
“Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.”
Publié en août dans @jaccjournals.bsky.social.
#MedSky #EndoSky
www.jacc.org/doi/10.1016/...
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients
www.jacc.org
November 2, 2025 at 1:06 PM
baladocritique.bsky.social
“Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial.”
Publié en octobre dans The Lancet Neurology.
#MedSky #NeuroSky
www.thelancet.com/journals/lan...
Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial
Daily administration of candesartan 16 mg is effective and well tolerated as a preventive treatment for episodic migraine. These findings support its role as a clinically meaningful and evidence-based...
www.thelancet.com
November 2, 2025 at 1:03 PM
baladocritique.bsky.social
“Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial).”
Publié en juillet dans Am J Gastroenterol.
#MedSky #GastroSky #LiverSky
journals.lww.com/ajg/abstract...
journals.lww.com
November 1, 2025 at 4:29 PM
Reposted by BaladoCritique : club de lecture médical
thecurbsiders.bsky.social
Digest 70: A Hearty Halloween Edition 👻

This week, The Curbsiders bring you treats for your brain, not tricks for your charting! 🍬

🫀 Aspirin + DOAC risk in chronic CAD
🧠 Interpreting CAC scores in symptomatic patients
🧬 Cancer genetics in the general population
…and more clinical goodies inside.
October 31, 2025 at 3:44 PM
baladocritique.bsky.social
"Effectiveness of Recombinant Herpes Zoster Vaccine in the U.S. Medicare Population, 2018 to 2019, by Immunocompetence and Prior Receipt of Live Zoster Vaccine."
Publié en octobre dans @annalsofim.bsky.social.
#MedSky #IDSky
www.acpjournals.org/doi/10.7326/...
Effectiveness of Recombinant Herpes Zoster Vaccine in the U.S. Medicare Population, 2018 to 2019, by Immunocompetence and Prior Receipt of Live Zoster Vaccine | Annals of Internal Medicine
Background: Recombinant zoster vaccine (RZV) was preferentially recommended over live zoster vaccine (ZVL) starting in 2018. Objective: To assess RZV effectiveness using target trial emulation, accoun...
www.acpjournals.org
October 31, 2025 at 11:52 AM
baladocritique.bsky.social
"Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC."
Publié ce jour dans le @nejm.org.
#MedSky
www.nejm.org/doi/full/10....
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC | NEJM
Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated EGFR (epidermal growth factor receptor)–mutated advanced non–small-cell l...
www.nejm.org
October 30, 2025 at 1:04 PM
baladocritique.bsky.social
“European Study of Prostate Cancer Screening - 23-Year Follow-up.”
Publié ce jour dans le @nejm.org.
#MedSky
www.nejm.org/doi/full/10....
European Study of Prostate Cancer Screening — 23-Year Follow-up | NEJM
The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because de...
www.nejm.org
October 30, 2025 at 11:07 AM
baladocritique.bsky.social
"Intensive Blood Pressure Control in Older Patients With Hypertension: 6-Year Results of the STEP Trial."
Publié ce jour dans #JACC.
#MedSky
www.jacc.org/doi/10.1016/...
Intensive Blood Pressure Control in Older Patients With Hypertension: 6-Year Results of the STEP Trial
www.jacc.org
October 28, 2025 at 4:18 PM